Uncover the hidden risks and cutting-edge advancements in HCM and Lp(a) management at PCNA’s Cardio Connections event. This virtual summit equips you with the latest evidence-based strategies to differentiate HCM subtypes, apply targeted therapies, and assess elevated Lp(a) as a critical CVD risk factor. Elevate your nursing practice with actionable insights on symptom management, guideline-directed care, and patient-centered care approaches to improve outcomes for high-risk populations.
Agenda
| Time | Session |
|---|---|
| 9:00 AM CT | Welcome |
| 9:15 AM CT | Hypertrophic Cardiomyopathy Care Evolving: From Symptom Control to Targeted Therapy |
| 10:00 AM CT | Product Theater presented by Boston Scientific |
| 10:55 AM CT | Lp(a): Lurking Under the Surface |
| 11:40 AM CT | Product Theater |
| 12:25 AM CT | Closing Remarks |
Learning Objectives
Hypertrophic Cardiomyopathy Care Evolving: From Symptom Control to Targeted Therapy
- Explain the pathophysiology and prevalence of HCM including differentiation between obstructive and non-obstructive HCM.
- Differentiate traditional pharmacologic and interventional HCM treatments from emerging disease-specific therapies, including mechanism of action, clinical effects, and role in symptom management.
- Apply evidence-based nursing assessment, monitoring, and patient education strategies for individuals with HCM receiving advanced pharmacologic therapies, including cardiac myosin
Lp(a): Lurking Under the Surface
- Examine Lp(a) as an independent risk factor for CVD highlighting testing strategies and urgency
- Take a deep dive into elevated Lp(a) CVD exacerbation and risk enhancement including PAD, MI, and stroke
- Review the latest guideline directed recommendations and clinical evidence for Lp(a) management
